|
|
|
|
|
|
| Mucinous Cystadenocarcinoma |
| Etiology • 10% of patients have evidence of ovarian or ovarian-breast cancer syndrome (see pathogenesis) • remainder sporadic |
| Pathogenesis • mutations in BRCA1 in a small number of cancer families, |
| Epidemiology • peri- or post-menopausal women of low parity • gonadal dysgenesis • ovarian epithelial cancer = 6% of female cancer and 50% of female cancer deaths due to late detection and failure to determine high risk group • mucinous = 10% of ovarian cancers; 20% bilateral |
| General Gross Description • capsule generally smooth • partially multicystic partially solid neoplasm • cyst fluid is sticky, yellow, and clear |
| General Microscopic Description • multiple glands composed of cells containing mucin • reminescent of intestinal adenocarcinoma • nuclear atypia and hyperchromasia with prominent nuclei • invasion of stroma with fibrosis: "desmoplasia" |
| Clinical Correlation • early symptoms vague, late abdominal distension with ascites and pain • rarely detected on routine examination • Stage I confined to ovary(ies), II confined to pelvis, III with extension to abdominal cavity, IV distant metasases • most women Stage III or IV at presentation • spread across serosal surfaces and to lymph nodes • removal of bulk of tumor and chemotherapy are major therapy |
| References • Cotran RS, Kumar V, Robbins SL: Robbins Pathologic Basis of Disease. 5th ed. Philadelphia, W.B. Saunders, 1994, pp. 1065-1068 |
| Mucinous Cystadenocarcinoma |
| Synopsis by: Melinda Sanders M.D. (T87000M84703)[41] |
| Search Medline at National Library of Medicine Please be patient during transfer. Medline will open in a new window. To return, close the Medline Window |
|
|
|
|
|
|